Systemic Inflammatory Response Syndrome Treatment Market Size 2026-2030
The systemic inflammatory response syndrome treatment market size is valued to increase by USD 5.12 billion, at a CAGR of 6.1% from 2025 to 2030. Increasing global incidence of sepsis and related inflammatory conditions will drive the systemic inflammatory response syndrome treatment market.
Major Market Trends & Insights
- North America dominated the market and accounted for a 35.8% growth during the forecast period.
- By Route of Administration - Intravenous segment was valued at USD 8.30 billion in 2024
- By Distribution Channel - Offline segment accounted for the largest market revenue share in 2024
Market Size & Forecast
- Market Opportunities: USD 7.94 billion
- Market Future Opportunities: USD 5.12 billion
- CAGR from 2025 to 2030 : 6.1%
Market Summary
What will be the Size of the Systemic Inflammatory Response Syndrome Treatment Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Request Free Sample
How is the Systemic Inflammatory Response Syndrome Treatment Market Segmented?
The systemic inflammatory response syndrome treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.
- Route of administration
- Intravenous
- Oral
- Distribution channel
- Offline
- Online
- End-user
- Hospitals
- Clinics
- Others
- Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Asia
- Rest of World (ROW)
- North America
By Route of Administration Insights
The intravenous segment is estimated to witness significant growth during the forecast period.
The Intravenous segment was valued at USD 8.30 billion in 2024 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 35.8% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Systemic Inflammatory Response Syndrome Treatment Market Demand is Rising in North America Request Free Sample
Market Dynamics
Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
What are the key market drivers leading to the rise in the adoption of Systemic Inflammatory Response Syndrome Treatment Industry?
What are the market trends shaping the Systemic Inflammatory Response Syndrome Treatment Industry?
What challenges does the Systemic Inflammatory Response Syndrome Treatment Industry face during its growth?
Exclusive Technavio Analysis on Customer Landscape
The systemic inflammatory response syndrome treatment market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the systemic inflammatory response syndrome treatment market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape of Systemic Inflammatory Response Syndrome Treatment Industry
Competitive Landscape
Companies are implementing various strategies, such as strategic alliances, systemic inflammatory response syndrome treatment market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
AbbVie Inc. -
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- AbbVie Inc.
- AstraZeneca Plc
- B.Braun SE
- Baxter International Inc.
- Becton Dickinson and Co.
- BioMerieux SA
- Dragerwerk AG and Co. KGaA
- Edwards Lifesciences Corp.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Fresenius Kabi AG
- Getinge AB
- GlaxoSmithKline Plc
- Johnson and Johnson Services
- Medtronic Plc
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Systemic inflammatory response syndrome treatment market
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Systemic Inflammatory Response Syndrome Treatment Market insights. See full methodology.
| Market Scope | |
|---|---|
| Page number | 289 |
| Base year | 2025 |
| Historic period | 2020-2024 |
| Forecast period | 2026-2030 |
| Growth momentum & CAGR | Accelerate at a CAGR of 6.1% |
| Market growth 2026-2030 | USD 5117.0 million |
| Market structure | Fragmented |
| YoY growth 2025-2026(%) | 5.7% |
| Key countries | US, Canada, Mexico, Germany, UK, France, Italy, The Netherlands, Spain, Russia, China, India, Japan, South Korea, Indonesia, Thailand, Singapore, Brazil, Australia, South Africa, UAE, Saudi Arabia and Turkey |
| Competitive landscape | Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Research Analyst Overview
What are the Key Data Covered in this Systemic Inflammatory Response Syndrome Treatment Market Research and Growth Report?
-
What is the expected growth of the Systemic Inflammatory Response Syndrome Treatment Market between 2026 and 2030?
-
USD 5.12 billion, at a CAGR of 6.1%
-
-
What segmentation does the market report cover?
-
The report is segmented by Route of Administration (Intravenous, and Oral), Distribution Channel (Offline, and Online), End-user (Hospitals, Clinics, and Others) and Geography (North America, Europe, Asia, Rest of World (ROW))
-
-
Which regions are analyzed in the report?
-
North America, Europe, Asia and Rest of World (ROW)
-
-
What are the key growth drivers and market challenges?
-
Increasing global incidence of sepsis and related inflammatory conditions, High rate of clinical trial failures due to patient heterogeneity
-
-
Who are the major players in the Systemic Inflammatory Response Syndrome Treatment Market?
-
AbbVie Inc., AstraZeneca Plc, B.Braun SE, Baxter International Inc., Becton Dickinson and Co., BioMerieux SA, Dragerwerk AG and Co. KGaA, Edwards Lifesciences Corp., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius Kabi AG, Getinge AB, GlaxoSmithKline Plc, Johnson and Johnson Services, Medtronic Plc, Merck and Co. Inc., Novartis AG, Pfizer Inc. and Sanofi SA
-
Market Research Insights
We can help! Our analysts can customize this systemic inflammatory response syndrome treatment market research report to meet your requirements.